Drop in the number of cancer diagnoses

A study from Macmillan Cancer Support suggests that cancer is going undiagnosed for up to 2,000 people a week due to COVID-19 concerns in hospitals and GP surgeries. The coronavirus pandemic has resulted in patients having appointments cancelled or postponed, or diagnostics being delayed because patients are concerned about attending hospital due to concerns about […]

read more

Surgical treatment of inferior vena cava tumour thrombi in kidney cancer

The formation of a cancerous blood clot, or thrombus, in one of the main veins that transport blood from the body to the heart, the inferior vena cava, can be a complication in patients with renal cell carcinoma (RCC), occurring in 5-15% of cases. A recent study investigated the surgical treatment of kidney cancer patients […]

read more

Quality of life worse for cancer patients during COVID-19 pandemic

A paper published in Psycho-Oncology┬áearlier this month suggests that patients with stage III and IV cancer have worse quality of life during the COVID-19 pandemic. Researchers from Lodz in Poland examined the quality of life of 238 patients with different types of stage III and IV cancer who were undergoing chemotherapy. Data from these patients […]

read more

Potential biomarker to predict outcomes in metastatic kidney cancer

A recent study published in Targeted Oncology last month investigates the role of an enzyme called ╬│-glutamyltransferase (GGT) as a potential biomarker for metastatic renal cell carcinoma (RCC). High levels of GGT in the blood has been linked with poor survival in various cancers; however, there are no data for metastatic RCC patients. This study […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

Potential screening blood test for early kidney cancer

Researchers at the Dana-Farber Cancer Institute in Boston, USA have used a DNA-sequencing blood test to identify some of the earliest signs of kidney cancer, for which a reliable screening test is not yet available. The researchers analysed sequences of DNA and tagged certain pieces of genetic code with molecules that alter their function. In […]

read more

12 Point-Plan to recovery of cancer services – letter to the Prime Minister

Chairs of the six All Party Parliamentary Groups related to cancer have written to the prime minister, Boris Johnson, to highlight the importance of the 12-Point Plan for restoration, recovery and transformation of cancer services following the COVID-19 pandemic: Covid and Cancer 12 point plan Read the 12-Point Plan to recovery letter here:    

read more

Shielding to stop at the end of July

There are 2.2 million people who have been self-isolating in England during the COVID-19 pandemic. Because infection rates are falling, these people will no longer need to shield from 1 August. Before the end of July, the shielding measures will be relaxed. From 6 July, people who have been shielding will be able to meet […]

read more

New targeted therapy shows potential for previously treated metastatic kidney cancer

A phase II study published in Frontiers in Oncology last month investigated the potential of a new targeted therapy called anlotinib for the treatment of people with metastatic renal cell carcinoma (RCC) that had already been treated with a VEGF tyrosine kinase inhibitor (TKI). Forty-two (42) patients were included in the study. The cancer progressed […]

read more

Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor. Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint […]

read more
Showing 1 to 10 of 818 results
  TOP